Business
Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day
Avidity is currently enrolling participants in the Phase 1/2 FORTITUDE™ study of AOC 1020 for the treatment of FSHD Company anticipates data from a
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"Avidity is currently enrolling participants in the Phase 1/2 FORTITUDE™ study of AOC 1020 for the treatment of FSHD \nCompany anticipates data from a preliminary assessment in half of the participants in the FORTITUDE study in 1H 2024\nSAN DIEGO, June 20, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), joins with the global community of patients, caregivers, and healthcare providers in support of World Facioscapulohumeral Muscular Dystrophy (FSHD) Day. FSHD is a serious, rare, hereditary muscle-weakening condition marked by life-long, progressive loss of muscle function that causes significant pain, fatigue, and disability. Currently, there are no approved therapies for the treatment of FSHD.\n\n \n \n \n \n \n \n\n \nFSHD is an autosomal dominant disease caused by the aberrant expression of the DUX4 (double homeobox 4) gene in the skeletal muscle, which activates genes that are toxic to muscle cells and leads to a series of downstream events that result in skeletal muscle wasting and compromised muscle function. FSHD affects both sexes equally, with onset typically in teenage and young adult years.\n\"We are grateful for our partnership with the global FSHD community as we collectively work together to advance AOC 1020 for the treatment of FSHD,\" said Sarah Boyce, president and chief executive officer at Avidity Biosciences. \"By directly targeting DUX4, AOC 1020 is designed to reduce the devastating effects of skeletal muscle wasting and progressive loss of muscle function in people living with FSHD. We are currently enrolling adults with FSHD into the AOC 1020 Phase 1/2 FORTITUDE™ study. We plan to share a preliminary assessment from the FORTITUDE study in the first half of next year.\"\nAvidity is currently enrolling participants in FORTITUDE, an ongoing randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial to evaluate the investigational therapy AOC 1020 in the treatment of FSHD. For more information about the FORTITUDE trial, visit the FORTITUDE study website or visit http://www.clinicaltrials.gov and search for NCT05747924.\n\"As the world's largest research-focused patient organization for FSHD, our mission is to find treatments and a cure for FSHD while e...